Abstract
Targeted intrapulmonary delivery of drugs may reduce systemic toxicity and improve treatment efficacy. In the current study, we evaluated the effects of a combination treatment consisting of inhalation of aerosolized liposomal amphotericin B (L-AMB) with intraperitoneal administration of micafungin (MCFG) against murine invasive pulmonary aspergillosis. The combination of aerosolized L-AMB with intraperitoneal MCFG significantly improved the survival rate, and the fungal burdens and histopathology findings after this treatment were superior to those of the control and both monotherapy groups.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Amphotericin B / administration & dosage
-
Amphotericin B / therapeutic use*
-
Animals
-
Antifungal Agents / administration & dosage
-
Antifungal Agents / therapeutic use*
-
Drug Therapy, Combination
-
Echinocandins / administration & dosage
-
Echinocandins / therapeutic use*
-
Female
-
Injections, Intraperitoneal
-
Invasive Pulmonary Aspergillosis / drug therapy*
-
Invasive Pulmonary Aspergillosis / pathology
-
Lipopeptides / administration & dosage
-
Lipopeptides / therapeutic use*
-
Lung / pathology
-
Micafungin
-
Mice
-
Mice, Inbred ICR
Substances
-
Antifungal Agents
-
Echinocandins
-
Lipopeptides
-
liposomal amphotericin B
-
Amphotericin B
-
Micafungin